DnB Asset Management’s Revance Therapeutics, Inc. RVNC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | – | Sell |
-60,229
| Closed | -$155K | – | 732 |
|
|
2024
Q2 | $155K | Buy |
60,229
+12,201
| +25% | +$31.4K | ﹤0.01% | 698 |
|
|
2024
Q1 | $236K | Buy |
48,028
+13,376
| +39% | +$65.7K | ﹤0.01% | 687 |
|
|
2023
Q4 | $305K | Buy |
34,652
+10,706
| +45% | +$94.1K | ﹤0.01% | 642 |
|
|
2023
Q3 | $275K | Buy |
23,946
+2,171
| +10% | +$24.9K | ﹤0.01% | 654 |
|
|
2023
Q2 | $551K | Buy |
21,775
+7,410
| +52% | +$188K | ﹤0.01% | 631 |
|
|
2023
Q1 | $462K | Buy |
14,365
+2,574
| +22% | +$82.9K | ﹤0.01% | 631 |
|
|
2022
Q4 | $218K | Buy |
+11,791
| New | +$218K | ﹤0.01% | 635 |
|